Generic

Linagliptin

Indications

Linagliptin is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults.

Pharmacology

Linagliptin is indicated to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4.

Dosage & Administration

Linagliptin 5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly.

Interaction

Linagliptin is a weak competitive and a weak to a moderate mechanism-based inhibitor of CYP isozyme CYP3A4 but does not inhibit other CYP isozymes.

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Side Effects

There may be hypoglycemia, nasopharyngitis, cough, and pancreatitis in combination with metformin and sulfonylurea.

Pregnancy & Lactation

Linagliptin tablets should be used during pregnancy only if clearly needed.

Precautions & Warnings

Hypersensitivity to the active substance or to any of the excipients.

Therapeutic Class

Dipeptidyl Peptidase-4 (DPP-4) inhibitor

Storage Conditions

Keep in a dry place away from light and heat.

Pharmaceutical Name

ACME Laboratories Ltd.